Three-year update of sildenafil citrate (viagra((R))) efficacy and safety

Citation
R. Sadovsky et al., Three-year update of sildenafil citrate (viagra((R))) efficacy and safety, INT J CL PR, 55(2), 2001, pp. 115-128
Citations number
98
Categorie Soggetti
General & Internal Medicine
Journal title
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
ISSN journal
13685031 → ACNP
Volume
55
Issue
2
Year of publication
2001
Pages
115 - 128
Database
ISI
SICI code
1368-5031(200103)55:2<115:TUOSC(>2.0.ZU;2-F
Abstract
In the three years since its launch, sildenafil citrate (Viagra (R)), an or al agent for the treatment of erectile dysfunction (ED), has been prescribe d to more than 10 million patients worldwide and has been further evaluated in clinical studies in diverse patient populations. Significant improvemen ts in erectile function have been demonstrated in double-blind, placebo-con trolled trials in patients with ED and underlying diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis, Promi sing results have also been reported for patients with treated prostate can cer, end-stage renal failure, Parkinson's disease, and spina bifida and in multiple organ transplant recipients. Accounts of sildenafil use in clinica l practice and postmarketing data reflect clinical trial findings of effect iveness in a broad spectrum of ED aetiologies and overall good tolerability . As in the clinical trials, most adverse events associated with sildenafil use have been transient, mild or moderate effects that rarely lead to trea tment discontinuation.